Shailina Keshwani

Shailina Keshwani

Auto-generated profile, based on publicly available information

Shailina Keshwani

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SSSteven M Smith
Steven M Smith
AWAlmut G. Winterstein
Almut G. Winterstein
MGMatthew Gurka
Matthew Gurka
MWMarta G. Walsh
Marta G. Walsh
SKShailina Keshwani
Shailina Keshwani
RCRhonda M Cooper-Dehoff
Rhonda M Cooper-Dehoff
Background: Knowledge of real‐world antihypertensive use is limited to prevalent hypertension, limiting our understanding of how treatment evolves and its contribution to persistently poor blood pressure control. We sought to characterize antihypertensive initiation among new users. Methods and Results: Using Medicaid and Medicare data from the OneFlorida+ Clinical Research Consortium, we identified new users of ≥1 first‐line antihypertensives (angiotensin‐converting enzyme inhibitor, calcium channel blocker, angiotensin receptor blocker, thiazide diuretic, or β‐blocker) between 2013 and 2021 among adults with diagnosed hypertension, and no antihypertensive fill during the prior 12 months. We evaluated initial antihypertensive regimens by class and drug overall and across study years and examined variation in antihypertensive initiation across demographics (sex, race, and ethnicity) and comorbidity (chronic kidney disease, diabetes, and atherosclerotic cardiovascular disease). We identified 143 054 patients initiating 188 995 antihypertensives (75% monotherapy; 25% combination therapy), with mean age 59 years and 57% of whom were women. The most commonly initiated antihypertensive class overall was angiotensin‐converting enzyme inhibitors (39%) followed by β‐blockers (31%), calcium channel blockers (24%), thiazides (19%), and angiotensin receptor blockers (11%). With the exception of β‐blockers, a single drug accounted for ≥75% of use of each class. β‐blocker use decreased (35%–26%), and calcium channel blocker use increased (24%–28%) over the study period, while initiation of most other classes remained relatively stable. We also observed significant differences in antihypertensive selection across demographic and comorbidity strata. Conclusions: These findings indicate that substantial variation exists in initial antihypertensive prescribing, and there remain significant gaps between current guideline recommendations and real‐world implementation in early hypertension care.

17 March 2025 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
ANAsinamai M. Ndai
Asinamai M. Ndai
KSKayla Smith
Kayla Smith
SKShailina Keshwani
Shailina Keshwani
JCJaeyoung Choi
Jaeyoung Choi
MLMichael Luvera
Michael Luvera
SSSteven M Smith
Steven M Smith

21 October 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
ANAsinamai M. Ndai
Asinamai M. Ndai
KSKayla Smith
Kayla Smith
SKShailina Keshwani
Shailina Keshwani
JCJaeyoung Choi
Jaeyoung Choi
MLMichael Luvera
Michael Luvera
SSSteven M Smith
Steven M Smith

6 October 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
GWGrace Hsin-Min Wang
Grace Hsin-Min Wang
EMEarl Morris
Earl Morris
SVScott M. Vouri
Scott M. Vouri
SKShailina Keshwani
Shailina Keshwani
SSStephan Schmidt
Stephan Schmidt
SSSteven M Smith
Steven M Smith

11 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ANAsinamai M. Ndai
Asinamai M. Ndai
KSKayla Smith
Kayla Smith
SKShailina Keshwani
Shailina Keshwani
JCJaeyoung Choi
Jaeyoung Choi
MLMichael Luvera
Michael Luvera
SSSteven M Smith
Steven M Smith
Objective: Angiotensin-II Receptor Blockers (ARBs) are commonly prescribed; however, their adverse events may prompt new drug prescription(s), known as prescribing cascades. We aimed to identify potential ARB-induced prescribing cascades using high-throughput sequence symmetry analysis. Methods: Using claims data from a national sample of Medicare beneficiaries (2011–2020), we identified new ARB users aged ≥66 years with continuous enrollment ≥360 days before and ≥180 days after ARB initiation. We screened for initiation of 446 other (non-antihypertensive) ‘marker’ drug classes within ±90 days of ARB initiation, generating sequence ratios (SRs) reflecting proportions of ARB users starting the marker class after versus before ARB initiation. Adjusted SRs (aSRs) accounted for prescribing trends over time, and for significant aSRs, we calculated the naturalistic number needed to harm (NNTH); significant signals were reviewed by clinical experts for plausibility. Results: We identified 320,663 ARB initiators (mean ± SD age 76.0 ± 7.2 years; 62.5% female; 91.5% with hypertension). Of the 446 marker classes evaluated, 17 signals were significant, and three (18%) were classified as potential prescribing cascades after clinical review. The strongest signals ranked by the lowest NNTH included benzodiazepine derivatives (NNTH 2130, 95% CI 1437–4525), adrenergics in combination with anticholinergics, including triple combinations with corticosteroids (NNTH 2656, 95% CI 1585–10074), and other antianemic preparations (NNTH 9416, 95% CI 6606–23784). The strongest signals ranked by highest aSR included other antianemic preparations (aSR 1.7, 95% CI 1.19–2.41), benzodiazepine derivatives (aSR 1.18, 95% CI 1.08–1.3), and adrenergics in combination with anticholinergics, including triple combinations with corticosteroids (aSR 1.12, 95% CI 1.03–1.22). Conclusion: The identified prescribing cascade signals reflected known and possibly under-recognized ARB adverse events in this Medicare cohort. These hypothesis-generating findings require further investigation to determine the extent and impact of these prescribing cascades on patient outcomes.

22 April 2025 in American Journal of Hypertension
Verified
Journal Article
Closed access
SKShailina Keshwani
Shailina Keshwani
KSKayla M Smith
Kayla M Smith
AWAlmut G Winterstein
Almut G Winterstein
MGMatthew J Gurka
Matthew J Gurka
MWMarta G Walsh
Marta G Walsh
SSSteven M Smith
Steven M Smith
BACKGROUND: Sex, race, and ethnicity disparities in hypertension (HTN) treatment intensity have been previously described. It remains unclear if these disparities occur at treatment onset and whether they can be explained by differences in clinical factors. METHODS: We conducted a retrospective cross-sectional study of adults with newly treated HTN using linked EHR + claims data from OneFlorida + Consortium. We included Florida Medicaid & Medicare-recipients diagnosed with HTN and prescribed ≥ 1 first-line antihypertensive during 2013–2020. We used generalized linear models to estimate differences in total therapeutic intensity score (TTIS)–a patient’s total daily dose (TDD) divided by recommended maximum TDD for a drug, summed across entire regimen–by sex, race, and ethnicity. We then modeled the same, controlling for demographics, blood pressure, and relevant comorbidities. RESULTS: In total 4,094 patients (mean age 58 ± 16; female 57.6%; White 56.7%) were included. We observed variations in the initiation of antihypertensive classes by sex, race and ethnicity. In univariate analyses, men averaged 7.6% (95% CI: 3.9%–11.3%) greater TTIS versus women and Black individuals averaged 10.5% (95% CI: 6.6%–14.3%) greater TTIS versus White individuals, whereas no disparities were observed by ethnicity. After adjusting for clinical factors, these disparities persisted: men had 7.6% (95% CI: 3.9%–11.4%) greater TTIS versus women, and Black individuals had 17.9% (95% CI: 13.8%–21.9%) greater TTIS versus White individuals. CONCLUSIONS: We observed disparities in treatment intensity by sex and race that were not explained by differences in clinical factors. There was sex-based variation in practice patterns, and Black individuals received more intensive initial antihypertensive therapy than White individuals.